Todos Medical starts trial of protease inhibitor to treat Covid-19 20 Apr 2021 (Last Updated April 20th, 2021 10:48) Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients. Share Article Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients. The 77-patient, randomised, double blind, placebo-controlled trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel. Todos Medical is developing the therapeutic agent Tollovir through a joint venture with NLC Pharma.